Aalberts N.V., together with its subsidiaries, offers mission-critical technologies for building, industry, and semicon markets in Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company operates through Building, Industry, and Semicon segments. It offers hydronic flow control systems for heating and cooling to enhance energy efficiency; integrated piping systems to distribute and control liquids and gas; advanced mechatronics specializing in vibration isolation, ultra precision frames, and high purity fluid systems; and surface technologies for surface treatments, heat treatments, polymer coatings, brazing, additive manufacturing, and post processing. It sells its products under the BROEN, Henco, ISIFLO, MIFA, and Metalis brands. The company was formerly known as Aalberts Industries N.V. and changed its name to Aalberts N.V. in April 2019. Aalberts N.V. was founded in 1975 and is headquartered in Utrecht, the Netherlands.…
Aalberts (ENXTAM:AALB) Stock Could Be 32% Undervalued On Cash Flow
Aalberts (AMS: AALB) is listed on Euronext Amsterdam, where its shares trade in EUR. It belongs to the Specialty Industrial Machinery industry, part of the Industrials sector, and reports about 13,000 employees.
The shares were at 38.50 EUR on 20 November 2026, up 52.1% over 52 weeks. Its 52-week range is 25.78 EUR to 45.22 EUR: the price is 14.9% below the high and 49.3% above the low.
At a market capitalisation of 4.08B EUR, it trades at 27.7 times trailing earnings and 11.3 times forward earnings. The median trailing P/E of its 20 largest Specialty Industrial Machinery peers is 27.6, so AALB is valued in line with them. It pays a dividend yielding 2.85% (it pays out 83% of its earnings), against a median of 1.67% among the dividend payers in that peer group.
Aalberts reports return on equity of 6.1%, an operating margin of 10.9% and flat revenue year over year.
Its debt exceeds its cash by 1.07B EUR, a debt-to-equity ratio of 0.45. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 10 analysts cover the stock, with an average rating of Buy; their mean price target of 49.88 EUR is 29.5% above the current price. The next earnings report is expected on 23 February 2027.